Literature DB >> 35135115

EGFR Inhibitor as Second-Line Therapy in a Patient With Mutant RAS Metastatic Colorectal Cancer: Circulating Tumor DNA to Personalize Treatment.

Paola Gazzaniga1, Cristina Raimondi1, Federica Urbano1, Enrico Cortesi1.   

Abstract

Entities:  

Year:  2018        PMID： 35135115     DOI： 10.1200/PO.17.00277

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  1 in total

1.  Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11).

Authors:  Y Sunakawa; H Satake; J Usher; Y Jaimes; Y Miyamoto; M Nakamura; M Kataoka; M Shiozawa; A Takagane; T Terazawa; T Watanabe; K Ishiguro; C Tanaka; M Takeuchi; M Fujii; K Danenberg; P V Danenberg; H-J Lenz; T Sekikawa; W Ichikawa
Journal:  ESMO Open       Date:  2022-06-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.